IDHC — Integrated Diagnostics Holdings Income Statement
0.000.00%
Last trade - 00:00
- $190.20m
- $205.66m
- EGP4.12bn
- 92
- 31
- 17
- 41
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,226 | 2,656 | 5,225 | 3,605 | 4,123 |
Cost of Revenue | |||||
Gross Profit | 1,084 | 1,343 | 2,804 | 1,462 | 1,524 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,436 | 1,671 | 2,963 | 2,773 | 3,385 |
Operating Profit | 791 | 986 | 2,262 | 832 | 738 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 758 | 969 | 2,232 | 854 | 737 |
Provision for Income Taxes | |||||
Net Income After Taxes | 505 | 609 | 1,493 | 527 | 468 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 511 | 594 | 1,413 | 541 | 510 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 511 | 594 | 1,413 | 541 | 510 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.852 | 0.99 | 2.35 | 0.925 | 0.901 |
Dividends per Share |